Mark K. White - Nov 17, 2023 Form 4 Insider Report for Annovis Bio, Inc. (ANVS)

Role
Director
Signature
/s/ Maria Maccecchini Attorney-in-Fact
Stock symbol
ANVS
Transactions as of
Nov 17, 2023
Transactions value $
$0
Form type
4
Date filed
7/3/2024, 05:18 PM
Previous filing
Apr 11, 2023
Next filing
Nov 22, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANVS Stock Option (right to buy) Award $0 +26.2K $0.00 26.2K Nov 17, 2023 Common Stock 26.2K $6.07 Direct F1, F2
transaction ANVS Stock Option (right to buy) Award $0 +2.15K $0.00 2.15K Nov 27, 2023 Common Stock 2.15K $7.39 Direct F2, F3
transaction ANVS Stock Option (right to buy) Award $0 +20K $0.00 20K Jul 1, 2024 Common Stock 20K $5.27 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 12, 2024, stockholders of Annovis Bio, Inc. ("the Company") approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved.
F2 The stock option shall vest immediately upon grant date.
F3 The stock option was granted in consideration for consulting services that reporting person will perform for the Company.
F4 The stock option shall vest in quarterly increments, based upon the services performed by the reporting person under the related Consulting Agreement.